Adaptive Biotechnologies CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Adaptive Biotechnologies reported significant revenue growth and a substantial reduction in net losses for 2025, driven by its MRD business and strategic partnerships.
NASDAQ
Adaptive Biotechnologies' 2024 revenue increased to $179.0 million, driven by a 42% growth in its MRD business, while operating expenses significantly decreased.
NASDAQ
10-K: Adaptive Biotechnologies Reports 2023 Results, Focuses on MRD Growth and Immune Medicine Pipeline
Adaptive Biotechnologies saw a revenue decrease in 2023, but also a significant growth in clonoSEQ test volume and progress in its immune medicine pipeline.